CytoTronics, a Boston, MA-based biotechnology company, raised $9.25M in Seed funding.
The round was led by Anzu Partners with participation from Milad Alucozai (BoxOne Ventures).
The company intends to use the funds to advance its platform that utilizes computer chip technology to conduct a suite of electrical and electrochemical cell-based assays.
Led by CEO Jeffrey Abbott, CytoTronics enables optics-free imaging for drug discovery through its complementary metal-oxide-semiconductor (CMOS) electronics platform. Building upon a suite of technologies licensed from Harvard University, the platform measures and manipulates live cells to produce real-time, high resolution electrical and electrochemical cell-based assays.
CytoTronics recently opened office space in the Agility Labs life sciences facility in Boston, MA, which is equipped with private dedicated biosafety level 2 wet biology labs and dry electronics labs, to continue research and further develop its platform.